[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eczema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eczema":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,57,85,121,150,178,202,230,259,283,309,333,371,395,440,460,482,506,533,558,582,606,632,673,690],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100629926","a-randomised-controlled-trial-of-eprom-guided-flexible-scheduling-in-dermatology-100629926",false,"NCT07481019","A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology","Inclusion Criteria:\n\n* Dermatology outpatients otherwise due for a follow-up appointment within six months.\n* Ability to independently navigate and complete ePROMs.\n* Ability to provide informed consent (including parental consent for minors).\n\nExclusion Criteria:\n\n* Patients who require fixed or scheduled in-person visits, including those needing skin cancer surveillance, bedside procedures (e.g., liquid nitrogen therapy), surgical interventions, or routine blood tests for immunosuppressive therapy.","ALL","16 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:\n\n* Does the intervention reduce the number of actualised outpatient visits over 12 months compared with standard fixed scheduling?\n* Does the intervention group achieve higher adherence to monthly ePROM monitoring, as measured by the proportion of completed ePROM submissions?",[26,27,28,29,30],"Chronic Dermatological Conditions","Eczema","Urticaria","Psoriasis","Acne",[32,33,34,35,36,37,38,39,40,41,42,43,44],"dermatology","flexible scheduling","patient initiated follow up","electronic patient-reported outcomes","ePROMs","Bayesian decision support","outpatient care","health services research","randomised controlled trial","implementation science","healthcare utilisation","appointment no-shows","value-based care","NOT_YET_RECRUITING","2026-06-29",{"date":48,"type":49},"2026-07-01","ACTUAL",{"date":51,"type":20},"2026-09",{"date":53,"type":20},"2029-12",{"name":55,"class":56},"National University Hospital, Singapore","OTHER",{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100570057","use-of-a-digital-psychotherapeutic-app-to-reduce-symptom-burden-in-dermatology-patients-100570057","NCT06702293","Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients","Development and Testing of a Digital Psychological Tool to Improve Symptom Burden in Dermatology Patients","Inclusion Criteria:\n\n* Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist\n* Aged 16 or older\n* Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)\n* Able to engage with a mobile application in the English language\n\nExclusion Criteria:\n\n* Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)\n* Patients with unstable psychiatric condition, characterized by\n\n  o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months\n* Patients with unstable dermatological condition, characterized by\n\n  * Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR\n  * Any of the following within 3 months\n\n    * inpatient admission for a dermatological condition\n    * Initiation of phototherapy\n    * Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.",{"count":65,"type":20},690,[23],"Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.",[27,29,28],[70,71,72,73,74,75,76],"digital health","eczema","psoriasis","urticaria","healthservices research","digital","mental health","RECRUITING",{"date":48,"type":49},{"date":80,"type":49},"2026-02-23",{"date":82,"type":20},"2029-07",{"name":55,"class":56},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":84},"100181078","phase-2-effects-of-treatments-on-atopic-dermatitis-100181078","NCT01631617","Effects of Treatments on Atopic Dermatitis","Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis","* INCLUSION CRITERIA:\n\nCohorts 1 \\[NO FURTHER ACCRUAL\\], 2 \\[INACTIVE\\], 4 \\[NO FURTHER ACCRUAL\\] and 5 \\[INACTIVE\\]: Healthy Volunteers\n\n* Males and females aged 18-50 years at time of initial protocol sampling\n* Subjects must participate fully and be willing to comply with the procedures of the protocol\n* Subjects must be co-enrolled in NIH protocol 08-HG-0059\n* Ability of subject to understand and provide written informed consent\n* Access to bathing facilities (Cohort 2 \\[INACTIVE\\])\n* Ability to swallow capsules or tablets\n\nCohort 3 \\[INACTIVE\\]: Atopic Dermatitis Patients\n\n* Subjects must be aged 2-50 years\n* Subjects must be co-enrolled in NIH protocol 08-HG-0059\n* Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party s Diagnostic Criteria for Atopic Dermatitis\n* Subjects must have a primary care provider\n* Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of greater than or equal to 15 indicating AD severity of moderate to severe\n* Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and\u002For pustules)\n* Access to bathing facilities\n* All subjects and\u002For their Legally Authorized Representative (LAR) must have the ability and agree to participate fully and comply with\n\nthe procedures of the protocol and provide informed consent. Pediatric patients will be included in age appropriate discussions and\n\nage appropriate assent will be obtained in accordance with NIH guidelines.\n\n-Ability of subject to understand and provide written informed consent\n\nCohort 6: Healthy Volunteers\n\n* Subjects previously enrolled in Cohorts 1 \\[NO FURTHER ACCRUAL\\] and 4 \\[INACTIVE\\] who completed on-protocol antibiotic regimen\n* Subjects must participate fully and be willing to comply with the procedures of the protocol\n* Ability of subject to understand and provide written informed consent\n\nEXCLUSION CRITERIA:\n\nCohorts 1 \\[NO FURTHER ACCRUAL\\] and 2 \\[INACTIVE\\]: Healthy Volunteers\n\n* Does not meet inclusion criteria\n* Any female with symptoms and\u002For serum hormone levels consistent with perimenopause or menopause\n* Use of systemic antibiotics in 12 months preceding baseline sampling\n* Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling\n* Use of topical or oral complementary\u002Falternative medicine (CAM) agents within 4 weeks of initiation of treatment\n* Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or lidocaine or epinephrine\n* Family history of toxic epidermal necrolysis\n* Known allergy or sensitivity to sodium hypochlorite (NaOCl)\n* History of AD or asthma\n* Inability to comply with the requirements of the protocol\n* Pregnant or lactating\n* Subjects with a primary or acquired immunodeficiency, including HIV seropositiviy\n* Any chronic past or present medical illness, including chronic skin diseases like psoriasis\n* Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants\n* Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as, assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals\n\nCohort 3 \\[INACTIVE\\]: Atopic Dermatitis Patients\n\n* Does not meet inclusion criteria\n* Any female with symptoms and\u002For serum hormone levels consistent with perimenopause or menopause\n* Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine\n* Family history of toxic epidermal necrolysis\n* Known allergic reaction to sodium hypochlorite (NaOCl)\n* Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended sampling sites within 3 weeks, prior to baseline sampling\n* Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling\n* Use of topical or oral CAM agents within 4 weeks of initiation of treatment\n* Subjects with known primary or acquired immunodeficiency\n* Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling\n* Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants within 7 days or 5 half-lives (whichever is the longer time period) of initiating treatment on this protocol\n* Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous 6 months\n* Pregnancy or lactating\n\nCohorts 4 \\[NO FURTHER ACCRUAL\\] and 5 \\[INACTIVE\\]: Healthy Volunteers\n\n* Does not meet inclusion criteria\n* Any female with symptoms and\u002For serum hormone levels consistent with perimenopause or menopause\n* Use of systemic antibiotics in 12 months preceding baseline sampling\n* Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling\n* Use of topical or oral complementary\u002Falternative medicine (CAM) agents within 4 weeks of initiation of treatment\n* (Cohort 4 \\[NO FURTHER ACCRUAL\\]) Known allergic reaction to sulfa class drugs; or lidocaine or epinephrine\n* (Cohort 5 \\[INACTIVE\\]) Known allergic reaction to tetracycline class drugs; or lidocaine or epinephrine\n* Family history of toxic epidermal necrolysis\n* History of AD or asthma\n* Inability to comply with the requirements of the protocol\n* Pregnant or lactating\n* Subjects with a primary or acquired immunodeficiency, including HIV seropositivity\n* Any chronic past or present medical illness, including chronic skin diseases like psoriasis\n* Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants\n* Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals\n\nCohort 6: Healthy Volunteers\n\n* Does not meet inclusion criteria\n* Use of swimming pools, hot tubs, or whirlpools in 7 days preceding sampling\n* Use of topical or oral CAM agents within 1 week or 4 weeks, respectively, prior to sampling\n* Pregnant or lactating females in all cohorts are excluded from participating due to the potential effects of the above listed antimicrobials on the developing human fetus or nursing infant; listed in Sections 11.1 through 11.5. Females of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Lactating mothers will discontinue breastfeeding prior to study enrollment.\n* Smokers and subjects who use smokeless tobacco products are excluded in all cohorts due to tobacco s unknown impact on human oral mucosa and microflora.",true,"2 Years","50 Years",{"count":96,"type":20},130,[98],"PHASE2","Background:\n\n\\- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin.\n\nObjectives:\n\n\\- To study the effect of eczema treatments on skin bacteria.\n\nEligibility:\n\n* Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis.\n* Healthy volunteers between 18 and 40 years of age with no history of eczema.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed.\n* All participants will be assigned to one of several study groups.\n* Healthy volunteers must not have taken antibiotics in the year before the start of the study.\n* All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits.\n* Healthy volunteers may be asked to come in for a one-time follow up after the 1 year mark.",[27,101,102,103,104],"Dermatitis","Skin Diseases, Genetic","Dermatitis, Atopic","Skin Diseases",[106,107,108,109,110],"Investigator-Blinded","Skin Biopsy","Randomized","Antibiotics","Topical","2026-06-27",{"date":113,"type":49},"2026-06-30",{"date":115,"type":49},"2012-09-18",{"date":117,"type":20},"2027-01-01",{"name":119,"class":120},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":92,"sex":16,"minAge":93,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":4,"leadSponsor":148,"locationsCount":84},"100103147","studies-of-skin-microbes-in-healthy-people-and-in-people-with-skin-conditions-100103147","NCT00605878","Studies of Skin Microbes in Healthy People and in People With Skin Conditions","Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients","* INCLUSION CRITERIA:\n\nInclusion Criteria for all groups\n\nMust have a primary care professional who will continue standard of care\u002Fevaluation in tandem with the protocol to whom information and recommendations can be communicated.\n\nInclusion Criteria for Group 1: Healthy Volunteers\n\nAdult males or females aged 18-50 at time of enrollment.\n\nInclusion Criteria for Group 2: AD patients\n\nA. Confirmed diagnosis of AD (UK Working Party s Diagnostic Criteria)24\n\nB. Moderate to severe AD SCORAD greater than or equal to 25(25)\n\nC. Greater than or equal to 1 affected antecubital (or popliteal) fossae at time of enrollment to serve as a target site.\n\nInclusion Criteria for Group 3: Healthy (pediatric) Controls\n\nA. Males or females 2-18 years of age.\n\nInclusion Criteria for Groups 4, 5, \\& 6: AD\u002FHIES\u002FWAS\u002FDOCK8 patients\n\nA. Must have mutation-proven diagnosis, with or without eczematous dermatitis.\n\nEXCLUSION CRITERIA:\n\nExclusion Criteria for all groups:\n\n1. Any subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants \\\u003C 7 days or 5 half-lives (whichever is the longer time period) of initiating this protocol.\n2. Any subjects who have cancer, and are currently or have previously received treatment with chemotherapy or radiation for treatment of malignancies within the previous 6 months.\n3. Any subject with a history of bone marrow transplant or gene therapy.\n\nExclusion Criteria specific for Group 2: AD patients\n\nA. Unable to remain off systemic (oral) antibiotics or systemic (oral) steroids for at least 7 days prior to body site sampling. Unable to temporarily discontinue use of topical steroids or calcineurin inhibitors for greater than or equal to 7 days to small areas of skin intended for sampling. (Topical therapies\u002Femollients for AD may be continued to non-adjacent, nontarget sites.)\n\nB. Underlying immunodeficiency, either as primary disease or secondary to treatment.\n\nExclusion Criteria specific for Groups 4, 5, \\& 6: HIES\u002FWAS\u002FDOCK8 patients:\n\nA. Unable to remain off topical steroids and emollients for preferably 7 days but at least 24 hours prior to body site sampling.\n\nExclusion Criteria specific for Groups 1 \\& 3: Healthy Volunteers and Healthy (pediatric) Controls:\n\nA. Any subjects with unstable or uncontrolled or chronic medical conditions requiring treatment or hospitalization. Individual determinations will be made at the discretion of the medical investigator.\n\nB. Underlying immunodeficiency, either as primary disease or secondary to treatment.\n\nC. Other documented chronic dermatologic disease, such as AD or psoriasis that may interfere with evaluation of the cutaneous microbiome. Common transient conditions, such as acne, are permissible.\n\nD. Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals.\n\nE. Subjects with asthma.\n\n5\\. Any female with symptoms and\u002For serum hormone levels consistent with perimenopause","100 Years",{"count":130,"type":20},530,"OBSERVATIONAL","This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.\n\nHealthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study.\n\nWe also wish to enroll children and adults aged 2-40 who have been diagnosed with inherited immune disorders known as HIES (hyperimmunoglobulin-E syndrome), WAS (Wiskott-Aldrich syndrome), or DOCK8 immunodeficiency because they frequently have skin problems similar to AD.\n\nEligible participants undergo the following tests and procedures:\n\n* Medical family and medication history\n* Skin examination\n* Blood tests (research blood as well as serum IgE, and complete blood count)\n* Skin samples to analyze microbes. Samples are obtained by the following methods: swabbing the skin with a cotton swab; scraping (scratching) the skin gently with a blade to remove only the outermost skin layers; and, only in adults, biopsy (surgical removal) of a small skin sample less than 1\u002F4-inch (5 mm) in diameter.\n* Nose swabs to analyze microbes.\n* Patients with eczema may have photographs of their skin taken to help monitor the skin rashes.\n\nParticipants may be contacted periodically for follow-up studies. Patients with atopic dermatitis may have additional skin samples collected to examine changes in the skin bacteria over time and during all of the stages of eczema. In addition, patients who have a flare of their eczema are asked to undergo a skin sample collection as soon as possible.",[27,134],"Atopic Dermatitis",[136,137,138,139,140,134,27,141,142],"Skin","Natural History","Microbiome","Bacteria","Atopic Dermatitis (Eczema)","Health Volunteer","HG","2026-06-23",{"date":145,"type":49},"2026-06-24",{"date":147,"type":49},"2008-01-22",{"name":149,"class":120},"National Human Genome Research Institute (NHGRI)",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":92,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100627317","phase-4-the-impact-of-dietary-salt-on-the-severity-of-eczema-100627317","NCT07447063","The Impact of Dietary Salt on the Severity of Eczema","iDOSE","Inclusion Criteria:\n\n* Participants ages 18 years\n* Willing and able to undergo non-contrast MRI.\n\nExclusion Criteria:\n\n* Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)\n* A cardiac event in the past 6 months\n* Impaired function of the liver or kidney (glomerular filtration rate \\\u003C60 mL\u002Fmin)\n* Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)\n* Antibiotic or immunomodulatory medications within the last month\n* Contraindications to sodium tablets\n\n(Topical medications used exclusively on the head\u002Fneck or hands\u002Ffeet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)","18 Years",{"count":159,"type":20},40,[161],"PHASE4","The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are:\n\n* Does a low-sodium diet improve eczema severity?\n* How does a low-sodium diet impact skin sodium concentration?\n* Is skin sodium concentration associated with eczema severity?\n\nResearchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake.\n\nParticipants will:\n\n* Follow a low-salt diet for the duration of the 24-week study\n* Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa\n* Complete up to 4 virtual check-in visits\n* Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI",[27,134],[165,166,167],"sodium","salt","diet","2026-06-05",{"date":170,"type":49},"2026-06-09",{"date":172,"type":20},"2026-06-22",{"date":174,"type":20},"2028-05-05",{"name":176,"class":56},"University of California, San Francisco",2,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":16,"minAge":93,"maxAge":128,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":84},"100523528","phase-2-cardamom-and-topical-roseomonas-in-atopic-dermatitis-100523528","NCT06096857","Cardamom and Topical Roseomonas in Atopic Dermatitis","A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Aged \\>=2 years\n2. Have a documented primary care provider near residence\n3. Fluency in English (applicable to participant or caregiver who will be answering questionnaires)\n4. Clinical diagnosis of AD, as defined by Hanifin and Rajka criteria, that has been present for \\>=3 months before the screening visit\n\n   * Major Criteria: Must have \\>=3 basic features:\n\n     * Pruritus\n     * Typical morphology and distribution (flexural lichenification in adults, facial and extensor eruptions in infants and children)\n     * Chronic or chronically relapsing dermatitis\n     * Personal or family history of atopy (asthma, allergic rhinitis, AD)\n   * Minor Criteria: Must have \\>=3 minor features:\n\n     * Xerosis\n     * Ichthyosis\u002Fpalmar hyperlinearity, keratosis pilaris\n     * Immediate (type 1) skin-test reactivity\n     * Raised serum IgE\n     * Early age of onset\n     * Tendency toward cutaneous infections (especially Staphylococcus aureus and herpes simplex), impaired cell-mediated immunity\n     * Tendency toward non-specific hand or foot dermatitis\n     * Nipple eczema\n     * Cheilitis\n     * Recurrent conjunctivitis\n     * Dennie-Morgan infraorbital fold\n     * Keratoconus\n     * Anterior subcapsular cataracts\n     * Orbital darkening\n     * Facial pallor, facial erythema\n     * Pityriasis alba\n     * Anterior neck folds\n     * Itch when sweating\n     * Intolerance to wool and lipid solvents\n     * Perifollicular accentuation\n     * Food intolerance\n     * Course influenced by environmental or emotional factors\n     * White dermographism, delayed blanch\n5. EASI \\>5 and\u002For an IGA \\>=1 at time of enrollment.\n6. Sexually active participants of childbearing potential must agree to use adequate methods of contraception from the screening visit continuously until 30 days after stopping treatment with the investigational product. Childbearing potential is defined for children as participants who have begun menstruating and for adults as participants who are not surgically sterile (hysterectomy and\u002For tubal ligation) or menopausal (age \\>=45 years plus no menses for 12 consecutive months without an alternative medical cause). Adequate contraception methods include: a barrier method (eg, condom use), oral contraceptive pill, hormonal patch or ring, hormonal injection, parenteral hormonal implant, or an intrauterine device.\n7. Participants and parents\u002Flegal guardians (for minor participants) are willing and able to comply with all study visits and\u002For study-related procedures.\n8. Participants\u002Fparents\u002Fguardians must have the ability to provide informed consent\u002Fassent as applicable.\n9. Willingness to perform visits virtually.\n\nEXCLUSION CRITERIA:\n\n1. Previous treatment of AD:\n\n   * Within 4 weeks prior to the baseline visit with any of the following:\n\n     * Immunosuppressive or immunomodulating systemic drugs such as systemic corticosteroids, azathioprine, methotrexate, cyclosporine\n     * Phototherapy or photochemotherapy for AD\n   * Within 12 weeks prior to the baseline visit with any of the following having been newly initiated:\n\n     * Topical steroids or topical calcineurin inhibitors\n     * Janus kinase (JAK) inhibitors (oral or topical)\n     * Dupilumab or any other biologic agent\n     * Topical PDE4 inhibitor\n     * Emollients containing ceramides, hyaluronic acid, urea or filaggrin degradation products.\n     * Bleach baths\n2. Active infection (chronic or acute) requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the baseline visit.\n3. Superficial skin infection requiring topical treatment within 1 week of baseline visit.\n4. Known or suspected history of immunosuppression or immunodeficiency.\n5. Existence of indwelling central line.\n6. Co-habitation with someone that has a known or suspected history of immunosuppression or immunodeficiency or has a central line.\n7. Any clinically significant laboratory, history, or exam findings that, in the investigator's opinion, would suggest an increased risk to the participant.\n8. Self-reported pregnancy or breastfeeding.\n9. Menstruating females who have not menstruated within 6 weeks prior to screening. Participants who have an intrauterine device or implanted long-term contraceptive agent that prevents them from menstruating regularly will not be excluded.",{"count":186,"type":20},120,[98],"Background:\n\nAtopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems. No cure exists for AD. Researchers know that people with AD have different kinds of harmless bacteria on their skin than do people without AD. They want to see if adding a harmless bacteria (Roseomonas mucosa) to the skin can help people with AD.\n\nObjective:\n\nTo test a skin treatment that contains R. mucosa and ground cardamom seeds in people with AD.\n\nEligibility:\n\nPeople aged 2 years and older with AD.\n\nDesign:\n\nAll study visits will be remote. Participants will have 5 visits over about 7 months.\n\nParticipants will be screened. Researchers will review their AD and medical history.\n\nParticipants will receive a study product in the mail. The product comes as a powder in single-use packets. Participants will be shown how to mix the powder with water in a single-use spray vial. They will spray the solution onto their skin 2 to 3 times per week for 14 weeks.\n\nHalf of participants will receive the study powder. Half will receive a placebo; the placebo looks just like the study powder but contains no bacteria. They will not know which one they have.\n\nDuring 3 study visits, participants will take a skin swab. They will receive supplies in the mail to rub a cotton swab on their skin and mail it back to the researchers.\n\nParticipants may opt to have pictures taken of their AD.\n\nParticipants will fill out 4 online questionnaires.",[134,27],[27,134,191,192,193,194],"Roseomonas","Cardamom","Itch","Rash",{"date":196,"type":49},"2026-06-08",{"date":198,"type":49},"2024-10-09",{"date":117,"type":20},{"name":201,"class":120},"National Institute of Allergy and Infectious Diseases (NIAID)",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":229},"100637567","phase-2-a-phase-2b-study-of-the-effects-of-camoteskimab-in-adults-with-moderate-to-severe-atopic-dermatitis-100637567","NCT07599813","A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Age 18-65 inclusive, at the time of signing the informed consent.\n2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.\n3. Participants with moderate-to-severe AD defined by:\n\n   1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.\n   2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.\n   3. EASI score of ≥ 16 at Screening and at Baseline.\n   4. Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed.\n4. Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.\n5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n6. Participant provides signed informed consent\n\nExclusion Criteria:\n\n1. History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.\n2. Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.\n3. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.\n4. Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.\n5. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.\n6. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.\n7. Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator.\n8. Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit.\n9. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test.\n10. Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+).\n11. Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled.\n12. Evidence of active or latent tuberculosis.\n13. Receipt of live or attenuated live vaccine within 6 weeks prior to screening.\n14. Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.\n15. Participant is known to have immune deficiency or is immunocompromised\n16. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of:\n\n    * Completely resected basal cell or squamous cell carcinoma of the skin.\n    * Carcinoma in situ of the cervix.\n17. Has had previous exposure to anti-IL-18 therapy.\n18. Known allergy\u002Fsensitivity to any component of IMP.\n19. History of use of any of these medications as follows:\n\n    1. Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline.\n    2. Systemic JAKi within 4 weeks prior to Baseline.\n    3. Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths.\n    4. Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral\u002Finjectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.\n    5. Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening.\n    6. Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening.\n    7. UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study.\n    8. PUVA treatment within 4 weeks prior to Baseline\n    9. Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline\n    10. Topical products containing urea within 1 week prior to Baseline\n    11. Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline\n    12. Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline.\n20. Female participant who is pregnant or breastfeeding or trying to conceive.\n21. Participant considered unlikely to adhere to treatment and\u002For follow the protocol in the opinion of the Investigator.","65 Years",{"count":211,"type":20},280,[98],"This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.",[134,215,101,103,216,27,217,218],"Atopic","Dermatologic Disease","Eczema Atopic Dermatitis","Eczema, Atopic","2026-05-29",{"date":221,"type":49},"2026-06-02",{"date":223,"type":49},"2026-05-28",{"date":225,"type":20},"2028-04-30",{"name":227,"class":228},"Apollo Therapeutics Ltd","INDUSTRY",85,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100595857","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-img-007-in-adult-participants-with-moderate-to-severe-atopic-dermatitis-100595857","NCT07037901","A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","ADAPTIVE","Key Inclusion Criteria:\n\n* Moderate-to-severe AD\n* Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable\n* Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception\n* Male participants must agree to use a highly effective method of contraception\n* EASI score ≥16\n* vIGA-AD score ≥3\n* ≥10% body surface area (BSA) of AD involvement\n* Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization\n\nKey Exclusion Criteria:\n\n* Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection\n* Evidence of active or latent tuberculosis (TB)\n* History of untreated or inadequately treated TB infection\n* Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals\n* Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement\n* Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study\n* Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit","74 Years",{"count":240,"type":20},405,[98],"The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.",[134,244,27],"Atopic Dermatitis Eczema",[246,134,103,101,27,104,247,248],"IMG-007","Immune System Diseases","Dermatologic Agents","2026-05-22",{"date":251,"type":49},"2026-05-27",{"date":253,"type":49},"2025-06-17",{"date":255,"type":20},"2028-08",{"name":257,"class":228},"Inmagene LLC",23,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":92,"sex":16,"minAge":157,"maxAge":209,"enrollmentInfo":266,"targetDuration":4,"studyType":21,"phases":268,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":84},"100627820","phase-1-ph-1a1b-single-ascending-dose-and-multiple-ascending-dose-study-of-arq-234-100627820","NCT07453602","Ph 1a\u002F1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234","A Phase 1a\u002F1b, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 in Healthy Volunteers and Subjects With Moderate to Severe Atopic Dermatitis.","Inclusion Criteria (All Participants):\n\n* Able and willing to provide written informed consent.\n* Adults 18-65 years (inclusive) at consent.\n* Generally healthy at screening\u002Fbaseline (no clinically significant findings on medical history, exam, vitals, ECG, or safety labs, per investigator).\n* Contraception requirements: Females of childbearing potential: negative pregnancy tests at screening and baseline and agree to use highly effective contraception (plus barrier method) during the study and for 4 months after last dose. Males if sexually active with a pregnant partner or a female of childbearing potential, agree to condom use during the study and for 4 months after last dose.\n* Body weight by study part: Part A (SAD) \\& Part B (MAD): 50-100 kg (inclusive), Part C (POC): 50-125 kg (inclusive)\n\nInclusion Criteria for atopic dermatitis (AD) Participants (Parts A Cohorts 6-7, Part B, Part C):\n\n* Diagnosis of moderate-to-severe atopic dermatitis for ≥ 6 months prior to screening.\n* Meets minimum disease severity at baseline: Part A Cohorts 6-7: BSA ≥7%, vIGA-AD 3-4, EASI ≥10 at Baseline, Parts B and C: BSA ≥10%, vIGA-AD 3-4, EASI ≥16 at Baseline.\n* Inadequate response, intolerance, or medical inappropriateness of topical AD therapies (and\u002For prior systemic AD therapy failure within the last year may qualify as inadequate response).\n\nExclusion Criteria (All Participants):\n\n* Any clinically significant medical or psychiatric condition that could increase risk, interfere with participation, or confound results (per investigator).\n* Significant renal impairment or clinically significant hepatic impairment (per protocol\u002Fpart-specific definitions).\n* Clinically significant cytopenias or clinically significant abnormal liver tests at screening (per protocol).\n* History of anaphylaxis\u002Fserious hypersensitivity (including significant hypersensitivity to local anesthetics).\n* History of attempted suicide or significant current risk, per investigator).\n* Chronic or significant infection history or positive screening tests for hepatitis B, hepatitis C, HIV, or tuberculosis (including positive QuantiFERON or history of active\u002Flatent TB).\n* Known\u002Fsuspected immunosuppression or history of invasive opportunistic infections or unusually frequent\u002Frecurrent\u002Fprolonged infections (per investigator).\n* Recent herpes zoster that poses risk or may affect interpretation (per investigator).\n* Malignancy within 5 years prior to screening\n* Positive urine drug screen at screening (Part A\u002FPart B only) or drug\u002Falcohol abuse within 12 months, or other condition likely to impair compliance (per investigator).\n* Unable to discontinue prohibited medications\u002Ftreatments per protocol.\n* Major surgery within 4 weeks prior to baseline or planned during participation.\n* Participation in another trial or receipt of investigational product within 12 weeks (or 5 half-lives, whichever longer) before baseline.\n* Prior cell-depleting therapy (e.g., rituximab) within 6 months prior to baseline (or until lymphocytes normalize, whichever longer).\n* Blood products within 4 weeks prior to baseline or planned during participation.\n* Live (attenuated) vaccines within 28 days prior to baseline or planned during the study.\n* Pregnant or breastfeeding, or planning pregnancy during the study or within 4 months after last dose.\n* Known\u002Fsuspected allergy to ARQ-234 or its excipients.\n* Unable to communicate\u002Funderstand the local language or otherwise unsuitable per investigator.\n* Family member of study staff or sponsor.\n\nExclusion Criteria for atopic dermatitis (AD) Participants (Parts A Cohorts 6-7, Part B, Part C):\n\n* Skin disease(s) other than AD that would interfere with assessments.\n* Active systemic\u002Flocal infection, including actively infected AD, or infection requiring oral\u002FIV antimicrobials within 14 days before baseline.\n* Phototherapy\u002Ftanning bed use within 4 weeks prior to baseline.\n* Biologic therapy for AD within 3 months or 5 half-lives (whichever longer) prior to baseline.\n* Expected need for rescue therapy for AD within the first 2 weeks after baseline.\n* History of eczema herpeticum within 12 months or ≥2 prior episodes.",{"count":267,"type":20},125,[269],"PHASE1","This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.",[272,27],"Atopic Dermatitis (AD)",[274],"ARQ-234","2026-05-20",{"date":249,"type":49},{"date":278,"type":49},"2026-03-02",{"date":280,"type":20},"2028-04",{"name":282,"class":228},"Arcutis Biotherapeutics, Inc.",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":84},"100620242","phase-2-a-double-blind-randomized-vehicle-controlled-phase-2-study-to-assess-the-efficacy-and-safety-of-gx-03-in-adult-subjects-with-moderate-to-severe-atopic-dermatitis-eczema-100620242","NCT07355075","A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)","A Double-Blind, Vehicle-Controlled Study to Assess the Efficacy of GX-03 When Used in a Population of Adult Individuals With Moderate to Severe Eczema","GX-03 in AD","Participants must meet all of the following criteria:\n\n* Adults aged 18 to 80 years, inclusive\n* Male or female subjects in good general health as determined by medical history\n* Presence of visible eczematous skin with disease severity consistent with moderate to severe eczema, as assessed by:\n* Eczema Area and Severity Index (EASI) or Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™)\n* Ability to read, understand, and provide written informed consent in English\n* Willingness and ability to comply with study procedures, including study visits and daily topical application\n* Agreement to use only the assigned study product on designated areas of interest for the duration of the study\n\nExclusion Criteria\n\nIndividuals meeting any of the following criteria will be excluded:\n\n* Pregnant, breastfeeding, or planning pregnancy during the study\n* Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments\n* Use of systemic or topical immunosuppressive therapies, including corticosteroids, within 3 weeks prior to enrollment\n* Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted\n* Use of topical medications at the test sites within 72 hours prior to enrollment\n* Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations\n* Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity","80 Years",{"count":293,"type":20},110,[98],"This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Subjects will be randomized in a 1:1 ratio to receive either GX-03 or vehicle control for 8 weeks.\n\nThe study is designed to evaluate improvement in investigator-assessed disease severity, itch, and patient-reported eczema symptoms following topical treatment with GX-03 compared with vehicle control. Efficacy assessments include the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), Eczema Area and Severity Index (EASI), Peak Pruritus Numeric Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM).\n\nAn interim assessment of conditional power for the primary efficacy endpoint will occur after the first 50 subjects complete the Week 8 visit or withdraw prematurely. Based on pre-specified criteria defined in the IDMC Charter, the IDMC may recommend continuation as planned, expansion of enrollment up to 200 subjects, or early curtailment of enrollment.",[217,27,134],[298,299,27,134],"Moderate-Severe AD","Moderate-Severe Eczema","2026-05-13",{"date":302,"type":49},"2026-05-18",{"date":304,"type":49},"2025-07-11",{"date":306,"type":20},"2026-07-10",{"name":308,"class":228},"Turn Therapeutics",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":84},"100637876","impact-of-a-daily-application-of-an-omega-3-monoglycerides-based-serum-and-cream-on-the-skin-microbiota-100637876","NCT07583121","Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota","Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Ratio of 4 Bacteria of the Skin Microbiota (Staphylococcus Aureus, Staphylococcus Epidermis, Cutibacterium Acnes and Streptococcus Pyogenes). Exploratory Study (COS-PBP-03).","COS-PBP-03","Inclusion Criteria:\n\n1. Participant aged of at least 18 years old.\n2. Participant diagnosed with eczema who did not use corticosteroids in the 14 days prior to study day 1;\n3. Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.\n4. Participant without intellectual problems likely to limit the validity of consent to participate in the study and compliance with protocol requirements, having the ability to cooperate adequately, understand and observe the instructions of research staff\n\nExclusion Criteria:\n\n* None",{"count":318,"type":20},10,[23],"This exploratory study aims to investigate the prebiotic potential of daily application of an omega-3 serum and cream to skin affected by eczema. The study will also collect data on any potential adverse effects of the products. Ten subjects will be enrolled in the study and will receive the same treatment for fourteen days. Their baseline condition before treatment will serve as a control for the effects observed after treatment on the targeted eczema area. A second area of eczema treated with the patient's usual skincare routine will also serve as a control.",[27],[323,324],"Skin hydration","Skin inflammation","2026-05-06",{"date":300,"type":49},{"date":328,"type":20},"2026-05-04",{"date":330,"type":20},"2026-12-18",{"name":332,"class":228},"SCF Pharma",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":341,"minAge":342,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":21,"phases":346,"briefSummary":347,"conditions":348,"keywords":355,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":84},"100619166","skin-inflammation-in-perimenopause-a-probiotic-intervention-proof-of-concept-trial-100619166","NCT07341087","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial (SIPPI)","SIPPI","Inclusion Criteria:\n\n1. Female, aged 40-60 years.\n2. Self-reported or clinician-diagnosed non-infectious, non-autoimmune inflammatory skin condition affecting the face (e.g., rosacea, acne, eczema).\n3. Willing and able to consume a daily oral intervention (2x 65 ml probiotic drinks or skimmed milk) for 8 weeks.\n4. Willing and able to provide sufficient blood, skin and stool samples at baseline and end-of-study (Week 8). Participants unable to provide adequate blood sample volumes will not be able to start the intervention.\n5. Willing and able to provide a photograph of the facial area, with all images anonymised for study purposes.\n6. Able to comply with study procedures, including attending clinic visits at KCL.\n7. Have access to a refrigerator at home and be able to store the study product(s) safely after collection (i.e., travel time allows safe storage).\n8. Capable of providing written informed consent.\n9. Have sufficient proficiency in English to complete study questionnaires and assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Inability or unwillingness to comply with study protocol requirements (e.g., clinic visits, sample provision, daily consumption of study drink)\n3. Unwilling to record dietary intakes using handwritten diet diaries\n4. Not fluent in the English language\n5. Is planning on international travel during the study period\n6. Current participation in another interventional clinical trial or having received an investigational\u002Fpharmaceutical product within the past 3 months.\n7. Known allergy or intolerance to dairy products, skimmed milk, or probiotic drinks containing Lactobacillus species.\n8. Currently pregnant, currently breastfeeding or planning to become pregnant in the next 4 months.\n9. BMI \\\u003C18.5kg\u002Fm2 or \\> 35kg\u002Fm2.\n10. Unintentional weight loss greater than 4 kg in the 3 months prior to enrolment.\n11. History of substance abuse or alcoholism (alcohol intake \\>50 units\u002Fweek) within the last 12 months.\n12. Current smokers, or individuals who quit smoking in the last 6-months.\n13. Fasting glucose \\>7mmol\u002Fl (finger prick test at baseline clinic).\n14. Active skin infection requiring systemic antibiotics, antivirals, or antifungals within the past 4 weeks.\n15. Major gastrointestinal disease (e.g., inflammatory bowel disease, celiac disease, short bowel syndrome) or history of significant gastrointestinal surgery (excluding appendectomy or cholecystectomy).\n16. Known immunodeficiency (e.g., HIV, immunosuppressive therapy, systemic corticosteroids \\>10 mg\u002Fday prednisolone equivalent).\n17. History of malignancy or clinically significant non-malignant skin conditions within the past 5 years (except adequately treated basal cell carcinoma).\n18. Serious medical conditions that, in the opinion of the investigator, would compromise safety or interfere with study outcomes (e.g., uncontrolled diabetes, advanced cardiovascular, hepatic, or renal disease, active cancer, autoimmune conditions).\n19. Women with a history of severe psychiatric illness that would limit adherence to study requirements.\n20. Current use of probiotics, prebiotics, or antibiotics within 4 weeks prior to baseline.\n21. Current use of systemic corticosteroids, or other immunosuppressive\u002Fimmunomodulatory therapies within the past 3 months.\n22. Currently receiving, or having received, phototherapy (e.g., UVB, PUVA, laser\u002Flight-based treatments, including at home treatments) for any skin condition within the past 3 months.\n23. Currently receiving, or having received, systemic dermatology treatments likely to affect skin inflammation or immune response within the past 3 months (e.g., isotretinoin, methotrexate, cyclosporine, biologics such as TNF, IL-17, IL-23 or IL-4\u002FIL-13 inhibitors).\n24. Currently receiving, or having received, topical treatments likely to significantly alter skin inflammation within the past 3 months (e.g., high-potency topical corticosteroids, topical calcineurin inhibitors such as tacrolimus or pimecrolimus, topical retinoids, or photodynamic therapy).\n25. Currently using, or have used, probiotic skincare (e.g., topical creams and serums) within the past 3 months.\n26. Currently receiving, have undergone, or plan to undergo cosmetic skin procedures (e.g., chemical peels, laser therapy, dermal fillers, microneedling) within the 3 months prior to, or within 3 months after the first (baseline) visit.\n27. Currently using, or have used, hormonal contraceptives or treatments known to exacerbate skin conditions, including Mirena (levonorgestrel-releasing intrauterine system), oral progesterone-only contraceptives (e.g., mini-pill), and synthetic progestogens (e.g., norethisterone) within the past 3 months.","FEMALE","40 Years","60 Years",{"count":345,"type":20},30,[23],"This study will explore whether a daily probiotic drink containing Lactobacillus casei Shirota (LcS) can help improve immune function and reduce inflammation in women going through the menopausal transition. Hormonal changes during this stage of life can affect the immune system, gut health, and skin, sometimes leading to increased inflammation or conditions such as eczema, acne or rosacea.\n\nParticipants will consume either a low-sugar LcS probiotic drink or a skimmed milk control drink every day for eight weeks. The study will assess markers of immune ageing, inflammation, skin health, wellbeing, and hormone levels. The results will help determine whether a safe, non-hormonal probiotic approach may support immune and skin health during the menopausal transition.",[349,350,351,352,27,353,30,354],"Skin Inflammation","Immunosenescence","Inflammation","Skin Health","Rosacea","Menopause",[356,357,358,359,360,361],"Probiotics","Lactobacillus casei Shirota","Immune ageing","Gut-skin axis","Skin health","Menopausal transition","2026-05-05",{"date":364,"type":49},"2026-05-08",{"date":366,"type":49},"2026-04-28",{"date":368,"type":20},"2027-11-01",{"name":370,"class":56},"King's College London",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":16,"minAge":378,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":382,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":394},"100578128","phase-3-a-study-of-the-medicine-called-abrocitinib-in-children-6-to-less-than-12-years-of-age-with-moderate-to-severe-eczema-100578128","NCT06807268","A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema","A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS","Inclusion Criteria Children aged 6 to \\\u003C12 years at the time of informed consent\u002Fassent.\n\n• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.\n\nDisease Characteristics:\n\nParticipants who meet all of the following AD criteria:\n\n* A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria\\[19\\]; and\n* A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and\n* Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy\n\nOther Inclusion Criteria:\n\nBody weight ≥15 kg\n\nExclusion Criteria\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical Conditions:\n\nAny medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n\nIf the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.\n\nHave any of the following medical conditions:\n\n* Infections:\n\n  * Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.\n  * History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.\n  * Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.\n  * Infection with HIV, hepatitis B, and\u002For hepatitis C\n  * Evidence of active TB or inadequately treated latent TB.\n* Skin Conditions:\n\n  \\- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.\n* Other Conditions:\n\n  * Documented history of skeletal dysplasia.\n  * Documented history of retinal detachment.\n  * History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.\n  * Prior history of leukemia, lymphoma, sarcoma or any other malignancy.\n  * Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.\n  * Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.\n\nPrior\u002FConcomitant Therapy:\n\nPrior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.\n\nConcomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.\n\nPrior\u002FConcurrent Clinical Study Experience:\n\nPrevious administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.","6 Years","11 Years",{"count":381,"type":20},150,[383],"PHASE3","This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \\\u003C12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.",[27],[101],{"date":325,"type":49},{"date":389,"type":49},"2025-07-24",{"date":391,"type":20},"2027-05-02",{"name":393,"class":228},"Pfizer",41,{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":341,"minAge":403,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":425,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":84},"100636706","improved-child-nutrition-and-development-through-social-transfers-100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams","12 Years",{"count":405,"type":20},1040,[23],"The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[409,410,411,412,413,414,415,416,417,418,419,420,421,422,27,423,424],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Infectious Diseases","Anemia","Child Development","Weight Loss","Blood Pressure","Mental Health","Diarrhea","Coughing","Allergies","Antibiotic Use",[426,427,428,429,76,430,431,432],"breastfeeding","cash transfer","child health","maternal health","child growth","child development","education",{"date":325,"type":49},{"date":435,"type":20},"2026-06-01",{"date":437,"type":20},"2028-02-28",{"name":439,"class":56},"Swiss Tropical & Public Health Institute",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":92,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":21,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":84},"100628549","clinical-evaluation-of-a-soothing-moisturizing-lotion-in-individuals-with-atopic-eczema-100628549","NCT07463079","Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema","Inclusion Criteria:\n\n* Healthy Malaysian women and men\n* Age above 18 years old\n* Clinically diagnosed with eczema with mild to moderate severity on any parts of the body as evaluated by Eczema Area and Severity Index (EASI) (score 10-20).\n\nExclusion Criteria:\n\n* History of allergies or adverse reactions to moisturizers or components of the specific products being tested\n* History of chronic allergies\n* Pregnant, breastfeeding women, or those planning pregnancy during the study period\n* Participants with documented autoimmune diseases.\n* Currently undergoing or requiring active drug treatment for atopic dermatitis or eczema\n* Use of any medication (topical or systemic) that could interfere with the study aim (e.g. corticosteroids, calcineurin inhibitors, methotrexate) 3 months prior to the start of the study treatment and throughout the study\n* Current participation in another interventional clinical study\n* Presence of dermatological or systemic disorder other than eczema that could interfere with study outcomes",{"count":447,"type":20},15,[23],"To investigate the safety and efficacy of the moisturizing lotion in improving eczema symptoms among individuals with atopic eczema in Malaysia. The study duration is 4 weeks and the skin assessment will be carried out at baseline and week 4.\n\nThe main questions this study aims to answer are:\n\n1. To investigate the safety of the moisturizing lotion for individuals with atopic eczema in Malaysia.\n2. To determine the efficacy of the moisturizing lotion in improving eczema lesions among individuals with atopic eczema in Malaysia.\n3. To assess the participants' satisfaction after using the moisturizing lotion.",[27],"2026-03-12",{"date":453,"type":49},"2026-03-16",{"date":455,"type":49},"2026-02-01",{"date":457,"type":20},"2026-05-30",{"name":459,"class":228},"USMARI Research & Innovation Centre",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":21,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":84},"100626881","phase-2-study-to-evaluate-soquelitinib-in-participants-with-moderate-to-severe-ad-100626881","NCT07441395","Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)","SIERRA1","Inclusion Criteria:\n\n* Adult male or female, ≥18 years of age, as applicable according to local legislation, at Screening.\n* Diagnosis of AD with onset of symptoms at least 1 year prior to the Screening visit.\n* Moderate to severe disease at screening and pre-randomization on Day 1 defined by:\n* EASI ≥16\n* Body surface area ≥10%\n* vIGA ≥3\n* PP-NRS average score of ≥4 over a period of 7 days prior to randomization at Day 1.\n* Documented history of prior topical and\u002For systemic therapy for AD within 6 months of randomization.\n* A female participant is eligible if she is not pregnant or breastfeeding, and is either of non-childbearing potential, OR of childbearing potential and agrees to use highly effective birth control\n\nExclusion Criteria:\n\n* Other concomitant skin conditions that would interfere with evaluations of the effect of study medication on AD.\n* Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 30 days of the Baseline visit or that could interfere with the appropriate assessment of AD lesions.\n* Known immunodeficiency syndrome, history of an invasive infection or active non skin-related infection requiring systemic anti-infective treatment within 30 days of Baseline.\n* History of immunosuppression not related to medication, history of clinically significant medical conditions, or any other reason which in the opinion of the investigator would interfere with the participant's participation in this study.\n* Have an unstable or uncontrolled illness, including but not limited to cerebrocardiovascular, respiratory, gastrointestinal, endocrine, hematologic, or neurologic disorders that would potentially affect participant safety within the study or confound efficacy and safety assessments.",{"count":469,"type":20},200,[98],"The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.\n\nThe study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check \"tolerability,\" which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them.\n\nTo understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it.\n\nParticipants will:\n\n* Take study treatment (soquelitinib or placebo) every day for 12 weeks\n* Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment",[134,244,27,218],"2026-03-03",{"date":475,"type":49},"2026-03-05",{"date":477,"type":20},"2026-02",{"date":479,"type":20},"2027-09",{"name":481,"class":228},"Corvus Pharmaceuticals, Inc.",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":92,"sex":16,"minAge":489,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":84},"100618581","flourish-exploring-the-early-infant-gut-microbiome-100618581","NCT07333482","Flourish: Exploring the Early Infant Gut Microbiome","Flourish Study: A Randomized, Three-Arm Longitudinal Clinical Study of Microbiome-Guided Interventions in Cesarean-Born Infants","Inclusion Criteria:\n\n* Infants are qualified for this study if they are 0 to 3 months of age at time of enrollment.\n* Infants must have been delivered via Cesarean delivery (C-section), either scheduled or emergent.\n* Infants must have been at least 36 weeks gestation at time of delivery.\n* Infants and their caregivers must reside in the United States with a US mailing address.\n\nExclusion Criteria:\n\n* Infants can not have been given probiotic supplements in their life at recruitment. This includes probiotic powder or supplements or formula with probiotic addition or multivitamin with probiotic addition.\n* Twin and multiple birth infants are not accepted in this study.\n* Infants cannot have the following existing health conditions:\n* Gastrointestinal conditions: Hirschsprung disease, eosinophilic gastrointestinal disorders (EGID) including eosinophilic esophagitis (EoE), necrotizing enterocolitis (NEC), short bowel syndrome (SBS)\n* Immune or auto-immune conditions: Severe Combined Immunodeficiency (SCID), human immunodeficiency virus (HIV)), excluding eczema and rashes\n* Congenital conditions: cleft lip or cleft palate, congenital heart disease, cerebral palsy, fragile X syndrome, down syndrome, spina bifida, cystic fibrosis, phenylketonuria (PKU), congenital hypothyroidism (CHT), galactosaemia)\n* Blood disorders (sickle cell disease, thalassemia, hemophilia)\n* Infant or any immediate family member has previously received results from an at-home microbiome stool test (excluding standard clinical diagnostic testing such as stool culture or pathogen testing)","0 Months","3 Months",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms.\n\nResearchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model.\n\nParticipants will:\n\n1. Provide six microbiome stool samples over a 24-month period.\n2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis.\n3. Receive microbiome reports and guidance according to their assigned study arm.\n4. Complete surveys on infant health history, symptoms, diet, and environmental exposures.\n5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported.\n\nThis study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.",[495,496,27,138],"Microbiota","Gut Microbiome","2026-02-20",{"date":499,"type":49},"2026-02-24",{"date":501,"type":49},"2026-01-31",{"date":503,"type":20},"2028-09",{"name":505,"class":228},"Seeding Inc",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":92,"sex":16,"minAge":489,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100610544","cutaneous-biomarkers-in-atopic-eczema-using-a-non-invasive-micro-suction-device-in-babies-100610544","NCT07228962","Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies","Using a Non-invasive Micro-suction Biomarker Extraction Device to Understand Atopic Eczema in Babies","CARE","Inclusion Criteria:\n\n1. Healthy babies and babies with atopic dermatitis up to 6 months old.\n2. Ability of parents\u002Fguardians\u002Fcaregivers to provide written informed consent for study participation.\n3. Willingness of parents\u002Fguardians\u002Fcaregivers to comply with all study requirements.\n4. Parents\u002Fguardians\u002Fcaregivers competent use of English language.\n\nExclusion Criteria:\n\n1. Parents\u002Fguardians\u002Fcaregivers unable to give informed consent.\n2. Preterm birth (defined as birth before 37 completed weeks gestation).\n3. Significant inflammatory skin disease at birth.\n4. Baby has any other serious health issue.","6 Months",{"count":345,"type":20},"This project aims to establish whether an adapted extraction device is tolerable and will be able to measure chemical signals in baby's ISF. Insight into the chemical profiles found in the skin interstitial fluid (ISF) of healthy and diseased babies will identify signals that can be used to investigate the causes of eczema and propose new preventative strategies and effective treatments.\n\nSpecifically, it aims to:\n\n1. Demonstrate that the developed ISF device can be used to extract biomarkers from the skin of babies non-invasively and is tolerable (not causing significant discomfort, bruising, or blister formation).\n2. Compare the profile of chemical markers present in the ISF of healthy babies with babies that have developed eczema.\n3. Compare the biomarker levels extracted from babies with eczema in lesional and non-lesional skin using the developed ISF device.\n4. Compare the microbiome and metabolome profiles from swabs taken from babies with healthy skin and with eczema in lesional and non-lesional skin (exploratory outcome).",[27,134,518],"Atopic Eczema",[27,134,520,521,522,523,138,524],"Immune System","Skin Barrier","Dermatology","Interstitial Skin Fluid","Early life","2026-02-09",{"date":527,"type":49},"2026-02-11",{"date":529,"type":20},"2026-03-31",{"date":531,"type":20},"2027-06-30",{"name":370,"class":56},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":92,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":541,"conditions":542,"keywords":545,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100617805","real-world-study-on-the-impact-of-atopic-dermatitis-from-a-caregiver-perspective-100617805","NCT07323394","Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Caregivers whose child has been diagnosed with severe atopic dermatitis ;\n2. Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);\n3. Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;\n4. Other parent or caregiver within the household of the child with atopic dermatitis.",{"count":540,"type":20},100,"This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.",[134,217,27,543,544],"Caregiver","Burden",[546,547,548],"atopic dermatitis","quality of life","real-world","2026-01-22",{"date":551,"type":49},"2026-01-23",{"date":553,"type":20},"2026-01",{"date":555,"type":20},"2026-07",{"name":557,"class":56},"PeriPharm",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":16,"minAge":565,"maxAge":566,"enrollmentInfo":567,"targetDuration":4,"studyType":21,"phases":568,"briefSummary":569,"conditions":570,"keywords":571,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":580,"locationsCount":4},"100621231","phase-4-comparative-study-of-crisaborole-vs-tacrolimus-in-atopic-dermatitis-100621231","NCT07367932","Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","Crisaborole 2% Versus Tacrolimus 0.03% Ointments for the Treatment of Mild to Moderate Atopic Dermatitis: A Comparative Study","Inclusion Criteria:\n\n* Patients with diagnosis of AD, according to Hanifin and Rajka criteria.\n* Patients of both genders\n* Age 5-25 years\n* Baseline Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3).\n\nExclusion Criteria:\n\n* Clinically infected eczema.\n* Baseline Investigator's Static Global Assessment (ISGA) score of severe (4).\n* Associated comorbidities that exacerbate pruritus.\n* Patients receiving topical treatment for AD and\u002For pruritus within the past 14 days and\u002For systemic treatment within the past month.\n* Pregnancy and lactation if in the childbearing period","5 Years","25 Years",{"count":345,"type":20},[161],"This study will compare the efficacy and safety of crisaborole ointment with tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis.",[103,27],[572,573,574],"Tacrolimus","Crisaborole","Atopic dermatitis","2026-01-20",{"date":577,"type":49},"2026-01-26",{"date":477,"type":20},{"date":555,"type":20},{"name":581,"class":56},"Cairo University",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":590,"conditions":591,"keywords":595,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":84},"100071017","blood-urine-and-tissue-collection-for-cutaneous-lymphoma-eczema-and-atopic-dermatitis-research-100071017","NCT00177268","Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research","Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research","Inclusion Criteria:\n\n* 18 or older\n* able and willing to provide informed consent\n* diagnosed with CTCL\n* diagnosed with either atopic dermatitis or eczema\n\nExclusion Criteria:\n\n* Lack of CTCL, atopic dermatitis, or eczema diagnosis in medical record",{"count":469,"type":20},"This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.",[592,593,594,27,134],"Cutaneous T-cell Lymphoma","Sezary Syndrome","Mycosis Fungoides",[592,593,594,596,71,546],"Blood\u002Ftissue banking","2025-12-23",{"date":599,"type":49},"2025-12-30",{"date":601,"type":49},"2004-10",{"date":603,"type":20},"2032-01",{"name":605,"class":56},"University of Pittsburgh",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":345},"100492208","a-study-to-learn-about-abrocitinib-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-100492208","NCT05689151","A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.","Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.","ADAIR","Inclusion Criteria:\n\n* Patients older than 18 years of age at inclusion.\n* Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.\n* Patients that have been informed of the study procedures and have signed the consent.\n\nExclusion Criteria:\n\n* Patients for whom abrocitinib is contraindicated.\n* Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.\n* Patients not affiliated to the French social security system.\n* Patients deprived of liberty, under guardianship, or unable to provide oral consent.\n* Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).",{"count":615,"type":20},183,"The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin.\n\nThis study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib.\n\nAll participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time.\n\nWe will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD.\n\nParticipants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).",[134,27],[574,619,27,620,621,622,101,215,623,32],"AD","Abrocitinib","JAK inhibitors","France","Inflammatory disease","2025-12-05",{"date":626,"type":49},"2025-12-08",{"date":628,"type":49},"2023-03-09",{"date":630,"type":20},"2027-12-31",{"name":393,"class":228},{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":92,"sex":341,"minAge":157,"maxAge":640,"enrollmentInfo":641,"targetDuration":4,"studyType":21,"phases":643,"briefSummary":644,"conditions":645,"keywords":656,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":84},"100559957","phase-3-vitamin-d-in-pregnancy-for-prevention-of-early-childhood-asthma-100559957","NCT06570889","VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma","VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma (VICTORY)","VICTORY","* Pregnant Danish women before week 26 with blood levels of EPA+DHA above 4.7% of total fatty acids\n* No current vitamin D intake above the recommended 400 IU\u002Fday\n* No endocrine-, heart-, kidney- or auto-immune disorders\n* No disorders requiring treatment with blood thinning medication","45 Years",{"count":642,"type":20},2000,[383],"The overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma\u002Fpersistent wheeze during the first three years of life as we hypothesize that supplementation in higher doses than recommended could reduce the risk of disease development.",[646,647,648,649,27,650,651,652,653,654,655],"Asthma","Respiratory Tract Infections","Gastrointestinal Infection","Croup","Allergy","Wheezing","Fractures, Bone","Development, Child","Cognition Disorders in Children","Psychiatric Diagnosis",[657,646,658,27,650,659,660,661,662,663],"Childhood","Infections","Development","Psychiatry","Bone development","Cognition","Growth","2025-09-24",{"date":666,"type":49},"2025-09-30",{"date":668,"type":49},"2024-12-20",{"date":670,"type":20},"2033-03",{"name":672,"class":56},"Professor Klaus Bønnelykke",{"id":674,"slug":675,"hasResults":12,"nctId":676,"briefTitle":677,"officialTitle":678,"acronym":679,"eligibilityCriteria":680,"healthyVolunteers":92,"sex":341,"minAge":157,"maxAge":640,"enrollmentInfo":681,"targetDuration":4,"studyType":21,"phases":682,"briefSummary":683,"conditions":684,"keywords":685,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":686,"startDateStruct":687,"completionDateStruct":688,"leadSponsor":689,"locationsCount":84},"100559140","phase-3-fish-oil-in-pregnancy-for-personalized-prevention-of-early-childhood-asthma-100559140","NCT06560255","Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma","Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma (FREYA)","FREYA","* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids\n* No planned use of fish oil supplementations\n* No endocrine-, heart-, kidney- or auto-immune disorders\n* No disorders requiring treatment with blood thinning medication",{"count":642,"type":20},[383],"The overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma\u002Fpersistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could reduce the risk of disease development.",[646,647,648,649,27,650,651,652,653,654,655],[657,646,658,27,650,659,660,661,662,663],{"date":666,"type":49},{"date":668,"type":49},{"date":670,"type":20},{"name":672,"class":56},{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":695,"acronym":696,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":16,"minAge":403,"maxAge":4,"enrollmentInfo":698,"targetDuration":699,"studyType":131,"phases":4,"briefSummary":700,"conditions":701,"keywords":703,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":715},"100543224","abrocitinib-taiwan-treatment-pattern-and-real-world-study-in-atopic-dermatitis-attract-registry-100543224","NCT06353087","Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)","The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib","ATTRACT","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Patients aged ≥12 years\n2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician\n3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions\n4. Evidence of a personally signed and dated informed consent\u002Fassent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will not be included in the study:\n\n1. Any prior use of abrocitinib\n2. Simultaneous participation in a study that includes administration of any investigational drug or procedure",{"count":469,"type":20},"12 Months","This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.",[103,101,27,104,247,702],"Janus Kinase Inhibitors",[134,620,621,704,705,706],"Real world","Registry","Taiwan","2025-09-02",{"date":709,"type":49},"2025-09-03",{"date":711,"type":49},"2024-07-01",{"date":713,"type":20},"2026-05-15",{"name":393,"class":228},8]